Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.45 | 2e-17 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.43 | 7e-11 |
mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.25 | 2e-08 |
mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.22 | 7e-08 |
mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.34 | 1e-07 |
mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-07 |
mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.29 | 1e-07 |
mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.33 | 2e-07 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.27 | 7e-07 |
mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.21 | 9e-07 |